MedTrace Logo

Evaluation of the Role of Genicular Nerve Block When Combined With Adductor Canal Block for Pain Control Following Knee Arthroscopy

NCT06951204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-30

No results posted yet for this study

Summary

The intervention tests the efficacy of Genicular nerve block when combined with Adductor canal block in comparison with Adductor canal block alone to control post operative pain in knee arthroscopy

Conditions

  • Post Operative Pain Control

Interventions

PROCEDURE

Adductor Canal Block (ACB) Only

All patients will receive adductor canal block under complete aseptic conditions using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ). while patient is laying supine lower limbs will slightly abducted at the hips and flexed at the knees , using linear ultrasound probe(2.5-7.5MHZ) on the anterior aspect of the patient's thigh, At the level of mid-thigh, by moving probe medially until the boat shaped Sartorius muscle is visualized , at which the adductor canal is identified beneath the sartorius muscle, 20ml bupivacaine (0.25%) will be injected in the canal after a careful negative aspiration. The spread of the drug lateral and around the femoral artery will be seen real time on ultrasound

PROCEDURE

Adductor canal block (ACB) combined with Genicular nerve block (GNB)

All patients will receive adductor canal block as described above under complete aseptic conditions then they will receive the genicular nerve block using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ), genicular nerve block will be done at three locations, i.e., superomedial, superolateral, and inferomedial locations of the condyle-shaft junction, while patient is lying supine linear ultrasound probe(2.5-7.5MHZ) will be used to target the superomedial, superolateral, and inferomedial genicular nerves,2ml bupivacaine (0.25%) will be injected in the 3 mentioned points after a careful negative aspiration

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-09-28
Completion
2024-09-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06951204 on ClinicalTrials.gov